Growing evidence indicates that anticancer agents can mobilize the immune system against the tumour. By reinstating immunosurveillance, the activity of conventional and targeted therapies might be prolonged beyond cessation of the treatment. The authors of this Review, explore how imatinib likely operates through immune and cell-autonomous mechanisms, which has practical implications for defining biomarkers that predict response or resistance to imatinib, as well as for the design of novel combination treatments.
- Laurence Zitvogel
- Sylvie Rusakiewicz
- Guido Kroemer
